A Randomized Study of Extended Treatment With Peginterferon alpha-2b Plus Ribavirin Based on Time to HCV RNA Negative-Status in Patients With Genotype 1b Chronic Hepatitis C

[Guest guest]

Am J Gastroenterol. 2009 Jan;104(1):70-5.

A Randomized Study of Extended Treatment With Peginterferon alpha-2b Plus

Ribavirin Based on Time to HCV RNA Negative-Status in Patients With Genotype 1b

Chronic Hepatitis C.

Ide T, Hino T, Ogata K, Miyajima I, Kuwahara R, Kuhara K, Sata M.

1Division of Gastroenterology, Department of Medicine, Kurume University School

of Medicine, Fukuoka-ken, Japan.

OBJECTIVES:The treatment of patients with hepatitis C virus (HCV) genotype 1

with peginterferon plus ribavirin treatment for more than 48 weeks demonstrated

high sustained virological response (SVR) rates. Although many studies extended

the duration of therapy from 48 weeks to 72 weeks, the optimal duration has not

yet been determined.METHODS:A total of 113 genotype 1b patients with high viral

load were randomized at baseline to the standard (n=56) or extended (n=57)

treatment group. The standard group patients received 48 weeks of peginterferon

plus ribavirin treatment. In the extended group, the treatment was performed for

44 weeks after patients became negative for HCV RNA (total duration 48-68

weeks).RESULTS:The SVR rate of the standard and extended group was 36% (20 of

56) and 53% (30 of 57; P=0.07). However, the extended group patients who became

negative for HCV RNA between weeks 16 and 24 had a significantly higher SVR rate

(78%; 7 of 9) than that of standard group (9%, 1 of 11; P=0.005). The predictive

factors for the SVR were the treatment regimen (the standard vs. extended

treatment) and the time to HCV RNA negative-status.CONCLUSIONS:The extended

treatment significantly increased the SVR rate in patients who were HCV RNA

negative at 16-24 weeks.

Am J Gastroenterol 2009; 104:70-75; doi:10.1038/ajg.2008.60.

PMID: 19098852 [PubMed - in process]